Paul Choi
Stock Analyst at Goldman Sachs
(3.22)
# 961
Out of 5,182 analysts
107
Total ratings
50.72%
Success rate
1.9%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals | Initiates: Buy | $40 | $15.92 | +151.26% | 1 | Apr 17, 2026 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.62 | +39.21% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $37.28 | +154.83% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $61.60 | +54.22% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $69.22 | -27.77% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $74.52 | +34.19% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $43.61 | +26.12% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $10.29 | -41.69% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $84.11 | -8.45% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $30.64 | -34.73% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $44.65 | +5.26% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $13.93 | -13.85% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $23.77 | -87.38% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.35 | +2,195.55% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $11.59 | -56.86% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $54.26 | -4.17% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $10.64 | +97.37% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $1.91 | +57.07% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $226.66 | -0.73% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.45 | +41.26% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $5.21 | +264.68% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.44 | +1,636.11% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $9.59 | +1,672.68% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $7.51 | +6.52% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $128.04 | +5.44% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $86.74 | +245.88% | 2 | Mar 30, 2020 |
Corvus Pharmaceuticals
Apr 17, 2026
Initiates: Buy
Price Target: $40
Current: $15.92
Upside: +151.26%
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $8.62
Upside: +39.21%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $37.28
Upside: +154.83%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $61.60
Upside: +54.22%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $69.22
Upside: -27.77%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $74.52
Upside: +34.19%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $43.61
Upside: +26.12%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $10.29
Upside: -41.69%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $84.11
Upside: -8.45%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $30.64
Upside: -34.73%
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $44.65
Upside: +5.26%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $13.93
Upside: -13.85%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $23.77
Upside: -87.38%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.35
Upside: +2,195.55%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.59
Upside: -56.86%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $54.26
Upside: -4.17%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $10.64
Upside: +97.37%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $1.91
Upside: +57.07%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $226.66
Upside: -0.73%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.45
Upside: +41.26%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $5.21
Upside: +264.68%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.44
Upside: +1,636.11%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $9.59
Upside: +1,672.68%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $7.51
Upside: +6.52%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $128.04
Upside: +5.44%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $86.74
Upside: +245.88%